{"id":65342,"date":"2026-05-14T20:41:32","date_gmt":"2026-05-14T12:41:32","guid":{"rendered":"https:\/\/flcube.com\/?p=65342"},"modified":"2026-05-14T20:41:33","modified_gmt":"2026-05-14T12:41:33","slug":"hansoh-pharma-receives-nmpa-approval-for-hs-10541-phase-i-trial-category-1-kras-g12c-inhibitor-targets-advanced-solid-tumors","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=65342","title":{"rendered":"Hansoh Pharma Receives NMPA Approval for HS-10541 Phase I Trial \u2013 Category 1 KRAS G12C Inhibitor Targets Advanced Solid Tumors"},"content":{"rendered":"\n<p><strong>Hansoh Pharmaceutical Group Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/3692:HKG\">HKG: 3692<\/a>) announced it has received <strong>regulatory approval from China&#8217;s National Medical Products Administration (NMPA)<\/strong> to initiate a <strong>clinical study<\/strong> for its <strong>HS-10541<\/strong>, a <strong>Category 1 innovative drug<\/strong> targeting <strong>advanced solid tumors with KRAS G12C mutations<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone-amp-development-framework\">Regulatory Milestone &amp; Development Framework<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Hansoh Pharmaceutical Group Co., Ltd. (HKG: 3692)<\/td><\/tr><tr><td><strong>Regulatory Authority<\/strong><\/td><td>National Medical Products Administration (NMPA), China<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Clinical trial authorization<\/td><\/tr><tr><td><strong>Drug Classification<\/strong><\/td><td>Category 1 innovative drug (highest priority in China)<\/td><\/tr><tr><td><strong>Target Population<\/strong><\/td><td>Advanced solid tumors with KRAS G12C mutations<\/td><\/tr><tr><td><strong>Development Stage<\/strong><\/td><td>Early clinical<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-target-rationale\">Drug Profile &amp; Target Rationale<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> <strong>HS-10541<\/strong> \u2013 proprietary KRAS G12C inhibitor<\/li>\n\n\n\n<li><strong>Target:<\/strong> <strong>KRAS G12C mutation<\/strong> \u2013 oncogenic driver in multiple solid tumor types<\/li>\n\n\n\n<li><strong>Therapeutic Area:<\/strong> <strong>Advanced solid tumors<\/strong> harboring specific KRAS G12C genetic alteration<\/li>\n\n\n\n<li><strong>Innovation Status:<\/strong> <strong>Category 1 designation<\/strong> provides regulatory exclusivity and accelerated pathways in China<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Selective inhibition of mutant KRAS G12C protein to block downstream oncogenic signaling<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-significance-amp-market-context\">Strategic Significance &amp; Market Context<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-kras-g12c-target-validation\">KRAS G12C Target Validation<\/h3>\n\n\n\n<p><strong>Clinical Precedent:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Amgen&#8217;s Lumakras (sotorasib)<\/strong> and <strong>Mirati&#8217;s Krazati (adagrasib)<\/strong> established proof-of-concept for KRAS G12C inhibition<\/li>\n\n\n\n<li><strong>FDA approvals<\/strong> in non-small cell lung cancer (NSCLC) validate target druggability and clinical benefit<\/li>\n\n\n\n<li><strong>Response rates:<\/strong> ~40% objective response rates in heavily pretreated NSCLC patients<\/li>\n<\/ul>\n\n\n\n<p><strong>Market Opportunity:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Prevalence:<\/strong> KRAS G12C mutations occur in ~13% of NSCLC, ~3% of colorectal cancer, and other solid tumors<\/li>\n\n\n\n<li><strong>Unmet Need:<\/strong> Limited treatment options after progression on standard therapies<\/li>\n\n\n\n<li><strong>Chinese Market:<\/strong> Significant patient population with KRAS-mutated cancers and growing demand for targeted therapies<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-competitive-differentiation-potential\">Competitive Differentiation Potential<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Next-Generation Inhibitor:<\/strong> Potential for improved potency, selectivity, or safety profile vs. existing KRAS G12C inhibitors<\/li>\n\n\n\n<li><strong>Domestic Innovation:<\/strong> First Chinese-developed KRAS G12C inhibitor could capture significant market share in Asia<\/li>\n\n\n\n<li><strong>Combination Opportunities:<\/strong> Future potential for combinations with immunotherapy, SHP2 inhibitors, or other targeted agents<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-strategy-amp-commercial-outlook\">Development Strategy &amp; Commercial Outlook<\/h2>\n\n\n\n<p>The NMPA approval positions Hansoh to become a key player in China&#8217;s emerging precision oncology market. As a <strong>Category 1 drug<\/strong>, HS-10541 benefits from:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Priority review pathways<\/strong> and potential accelerated approval<\/li>\n\n\n\n<li><strong>Extended market exclusivity<\/strong> protecting commercial returns<\/li>\n\n\n\n<li><strong>Premium pricing opportunities<\/strong> for innovative targeted therapies<\/li>\n\n\n\n<li><strong>Strategic partnerships<\/strong> potential with global pharmaceutical companies<\/li>\n<\/ul>\n\n\n\n<p>Success in clinical development could establish Hansoh as a leader in molecularly-targeted oncology therapies, complementing the company&#8217;s existing portfolio of established pharmaceutical products.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-pipeline-implications-amp-strategic-evolution\">Pipeline Implications &amp; Strategic Evolution<\/h2>\n\n\n\n<p>This KRAS G12C program represents Hansoh&#8217;s strategic pivot toward <strong>innovative targeted oncology therapies<\/strong>, moving beyond traditional pharmaceutical manufacturing into cutting-edge precision medicine. The company&#8217;s investment in KRAS inhibition demonstrates commitment to addressing high-value, genetically-defined patient populations with significant unmet medical needs.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development timelines, regulatory approvals, and therapeutic potential of HS-10541. Actual results may differ due to risks including clinical trial outcomes, regulatory requirements, competitive dynamics, and market conditions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2026051301219_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026051301219_c.\"><\/object><a id=\"wp-block-file--media-5606814f-c831-44d0-9cdd-43c1472df3bb\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2026051301219_c.pdf\">2026051301219_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2026051301219_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-5606814f-c831-44d0-9cdd-43c1472df3bb\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Hansoh Pharmaceutical Group Co., Ltd. (HKG: 3692) announced it has received regulatory approval from China&#8217;s&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,62,363,1182],"class_list":["post-65342","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-cancer","tag-clinical-trial-approval-initiation","tag-hansoh-pharmaceutical","tag-hkg-3692"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Hansoh Pharma Receives NMPA Approval for HS-10541 Phase I Trial \u2013 Category 1 KRAS G12C Inhibitor Targets Advanced Solid Tumors - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Hansoh Pharmaceutical Group Co., Ltd. (HKG: 3692) announced it has received regulatory approval from China&#039;s National Medical Products Administration (NMPA) to initiate a clinical study for its HS-10541, a Category 1 innovative drug targeting advanced solid tumors with KRAS G12C mutations.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=65342\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hansoh Pharma Receives NMPA Approval for HS-10541 Phase I Trial \u2013 Category 1 KRAS G12C Inhibitor Targets Advanced Solid Tumors\" \/>\n<meta property=\"og:description\" content=\"Hansoh Pharmaceutical Group Co., Ltd. (HKG: 3692) announced it has received regulatory approval from China&#039;s National Medical Products Administration (NMPA) to initiate a clinical study for its HS-10541, a Category 1 innovative drug targeting advanced solid tumors with KRAS G12C mutations.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=65342\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-14T12:41:32+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-14T12:41:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65342#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65342\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Hansoh Pharma Receives NMPA Approval for HS-10541 Phase I Trial \u2013 Category 1 KRAS G12C Inhibitor Targets Advanced Solid Tumors\",\"datePublished\":\"2026-05-14T12:41:32+00:00\",\"dateModified\":\"2026-05-14T12:41:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65342\"},\"wordCount\":486,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Cancer\",\"Clinical trial approval \\\/ initiation\",\"Hansoh Pharmaceutical\",\"HKG: 3692\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65342#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65342\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=65342\",\"name\":\"Hansoh Pharma Receives NMPA Approval for HS-10541 Phase I Trial \u2013 Category 1 KRAS G12C Inhibitor Targets Advanced Solid Tumors - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-14T12:41:32+00:00\",\"dateModified\":\"2026-05-14T12:41:33+00:00\",\"description\":\"Hansoh Pharmaceutical Group Co., Ltd. (HKG: 3692) announced it has received regulatory approval from China's National Medical Products Administration (NMPA) to initiate a clinical study for its HS-10541, a Category 1 innovative drug targeting advanced solid tumors with KRAS G12C mutations.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65342#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65342\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65342#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hansoh Pharma Receives NMPA Approval for HS-10541 Phase I Trial \u2013 Category 1 KRAS G12C Inhibitor Targets Advanced Solid Tumors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hansoh Pharma Receives NMPA Approval for HS-10541 Phase I Trial \u2013 Category 1 KRAS G12C Inhibitor Targets Advanced Solid Tumors - Insight, China&#039;s Pharmaceutical Industry","description":"Hansoh Pharmaceutical Group Co., Ltd. (HKG: 3692) announced it has received regulatory approval from China's National Medical Products Administration (NMPA) to initiate a clinical study for its HS-10541, a Category 1 innovative drug targeting advanced solid tumors with KRAS G12C mutations.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=65342","og_locale":"en_US","og_type":"article","og_title":"Hansoh Pharma Receives NMPA Approval for HS-10541 Phase I Trial \u2013 Category 1 KRAS G12C Inhibitor Targets Advanced Solid Tumors","og_description":"Hansoh Pharmaceutical Group Co., Ltd. (HKG: 3692) announced it has received regulatory approval from China's National Medical Products Administration (NMPA) to initiate a clinical study for its HS-10541, a Category 1 innovative drug targeting advanced solid tumors with KRAS G12C mutations.","og_url":"https:\/\/flcube.com\/?p=65342","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-14T12:41:32+00:00","article_modified_time":"2026-05-14T12:41:33+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=65342#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=65342"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Hansoh Pharma Receives NMPA Approval for HS-10541 Phase I Trial \u2013 Category 1 KRAS G12C Inhibitor Targets Advanced Solid Tumors","datePublished":"2026-05-14T12:41:32+00:00","dateModified":"2026-05-14T12:41:33+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=65342"},"wordCount":486,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Cancer","Clinical trial approval \/ initiation","Hansoh Pharmaceutical","HKG: 3692"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=65342#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=65342","url":"https:\/\/flcube.com\/?p=65342","name":"Hansoh Pharma Receives NMPA Approval for HS-10541 Phase I Trial \u2013 Category 1 KRAS G12C Inhibitor Targets Advanced Solid Tumors - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-14T12:41:32+00:00","dateModified":"2026-05-14T12:41:33+00:00","description":"Hansoh Pharmaceutical Group Co., Ltd. (HKG: 3692) announced it has received regulatory approval from China's National Medical Products Administration (NMPA) to initiate a clinical study for its HS-10541, a Category 1 innovative drug targeting advanced solid tumors with KRAS G12C mutations.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=65342#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=65342"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=65342#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Hansoh Pharma Receives NMPA Approval for HS-10541 Phase I Trial \u2013 Category 1 KRAS G12C Inhibitor Targets Advanced Solid Tumors"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65342","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=65342"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65342\/revisions"}],"predecessor-version":[{"id":65344,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65342\/revisions\/65344"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=65342"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=65342"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=65342"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}